Silence Therapeutics Q3 net loss narrows 41% to $12.43 million

Bitget2026/11/12 13:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Silence Therapeutics’ third-quarter 2026 net loss narrowed 41% year over year to $12.43 million.
No revenue was recorded for the quarter, compared with $159,000 a year earlier.
R&D expenses fell 55% to $9.3 million, mainly due to completed zerlasiran Phase 3 readiness work and reduced personnel costs.
Cash and cash equivalents totaled $247.7 million at September 30, including $201.3 million in gross public-offering proceeds.
Merck KGaA agreed to acquire the business, with closing expected in the first quarter of 2027, subject to customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silence Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20261112837093) on November 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Silence Therapeutics Q3 net loss narrows 41% to $12.43 million

You may also like

Crypto prices